通过药理和直接电交感刺激增加心房传导速度
Timothy M Markman1, Lingyu Xu1, Sohail Zahid2
1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
JACC. Clinical electrophysiology
|October 4, 2024
概括
通过脊髓静脉 (VV) 电脉冲或异二醇进行交感刺激,可增强心房导电速度 (CV) 并降低其异质性. 这些发现为管理心房动提供了洞察力.
科学领域:
- 心血管电生理学 心血管电生理学
- 自主神经系统的调节规则
- 心律不整的心脏病理生理病理学
背景情况:
- 心房导电速度 (CV) 在心房动等复发性心律失常中至关重要.
- 自主音调显著影响心房心血管.
- 通过脊髓静脉 (VV) 电刺激,可以诱导心交感神经的激活.
研究的目的:
- 在交感刺激过程中对右心房 (RA) CV 变化的特征.
- 为了比较药理学 (异二醇) 和直接电 (VV刺激) 对RA CV的交感激活效应.
主要方法:
- 在鼻腔节律 (SR) 中对右心房 (RA) 的电解剖学映射.
- 在右脊椎静脉 (VV) 刺激 (20 Hz) 期间绘制RA映射.
- 在异二醇输注期间绘制RA图,定位为VV刺激心率.
主要成果:
- 与SR相比,脊椎静脉 (VV) 刺激和异二醇显著增加了RACV (P < 0.001).
- 这两种刺激方法都减少了RA CV异质性 (P < 0.001).
- 心血管和异质性的变化与心率无关,因为RA节拍没有显著影响.
结论:
- 全球RA CV通过通过右侧VV的同情刺激来增强.
- 交感刺激减少了RACV的异质性.
- 这些发现表明,对心房的管理有潜在的治疗意义.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
716
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
716
Conduction System of the Heart
4.7K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
4.7K
Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
Electrophysiology of Normal Cardiac Rhythm
2.3K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.3K
Mechanism of Cardiac Arrhythmias
894
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
894
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395


